Switch theme
Sign up to access all valuation multiples
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
1933
34.1K+
LTM Revenue $47.4B
LTM EBITDA $11.4B
$138B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bristol-Myers Squibb has a last 12-month revenue (LTM) of $47.4B and a last 12-month EBITDA of $11.4B.
In the most recent fiscal year, Bristol-Myers Squibb achieved revenue of $48.3B and an EBITDA of $3.2B.
Bristol-Myers Squibb expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bristol-Myers Squibb valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $47.4B | XXX | $48.3B | XXX | XXX | XXX |
| Gross Profit | $35.1B | XXX | $34.3B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $11.4B | XXX | $3.2B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $10.1B | XXX | $5.9B | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $7.2B | XXX | -$8.9B | XXX | XXX | XXX |
| Net Margin | 15% | XXX | -19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $39.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bristol-Myers Squibb's stock price is $48.
Bristol-Myers Squibb has current market cap of $98.3B, and EV of $138B.
See Bristol-Myers Squibb trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $138B | $98.3B | XXX | XXX | XXX | XXX | $3.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bristol-Myers Squibb has market cap of $98.3B and EV of $138B.
Bristol-Myers Squibb's trades at 2.9x EV/Revenue multiple, and 43.5x EV/EBITDA.
Equity research analysts estimate Bristol-Myers Squibb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bristol-Myers Squibb has a P/E ratio of 13.7x.
See valuation multiples for Bristol-Myers Squibb and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $98.3B | XXX | $98.3B | XXX | XXX | XXX |
| EV (current) | $138B | XXX | $138B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 43.5x | XXX | XXX | XXX |
| EV/EBIT | 13.7x | XXX | 23.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.7x | XXX | -11.0x | XXX | XXX | XXX |
| EV/FCF | 9.3x | XXX | 9.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBristol-Myers Squibb's last 12 month revenue growth is -5%
Bristol-Myers Squibb's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.8M for the same period.
Bristol-Myers Squibb's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bristol-Myers Squibb's rule of X is 11% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bristol-Myers Squibb and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 61% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bristol-Myers Squibb acquired XXX companies to date.
Last acquisition by Bristol-Myers Squibb was XXXXXXXX, XXXXX XXXXX XXXXXX . Bristol-Myers Squibb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bristol-Myers Squibb founded? | Bristol-Myers Squibb was founded in 1933. |
| Where is Bristol-Myers Squibb headquartered? | Bristol-Myers Squibb is headquartered in United States of America. |
| How many employees does Bristol-Myers Squibb have? | As of today, Bristol-Myers Squibb has 34.1K+ employees. |
| Who is the CEO of Bristol-Myers Squibb? | Bristol-Myers Squibb's CEO is Dr. Christopher S. Boerner, PhD. |
| Is Bristol-Myers Squibb publicy listed? | Yes, Bristol-Myers Squibb is a public company listed on NYS. |
| What is the stock symbol of Bristol-Myers Squibb? | Bristol-Myers Squibb trades under BMY ticker. |
| When did Bristol-Myers Squibb go public? | Bristol-Myers Squibb went public in 1952. |
| Who are competitors of Bristol-Myers Squibb? | Similar companies to Bristol-Myers Squibb include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bristol-Myers Squibb? | Bristol-Myers Squibb's current market cap is $98.3B |
| What is the current revenue of Bristol-Myers Squibb? | Bristol-Myers Squibb's last 12 months revenue is $47.4B. |
| What is the current revenue growth of Bristol-Myers Squibb? | Bristol-Myers Squibb revenue growth (NTM/LTM) is -5%. |
| What is the current EV/Revenue multiple of Bristol-Myers Squibb? | Current revenue multiple of Bristol-Myers Squibb is 2.9x. |
| Is Bristol-Myers Squibb profitable? | Yes, Bristol-Myers Squibb is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bristol-Myers Squibb? | Bristol-Myers Squibb's last 12 months EBITDA is $11.4B. |
| What is Bristol-Myers Squibb's EBITDA margin? | Bristol-Myers Squibb's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Bristol-Myers Squibb? | Current EBITDA multiple of Bristol-Myers Squibb is 12.1x. |
| What is the current FCF of Bristol-Myers Squibb? | Bristol-Myers Squibb's last 12 months FCF is $14.8B. |
| What is Bristol-Myers Squibb's FCF margin? | Bristol-Myers Squibb's last 12 months FCF margin is 31%. |
| What is the current EV/FCF multiple of Bristol-Myers Squibb? | Current FCF multiple of Bristol-Myers Squibb is 9.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
